Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

MM31: Treatment Update in Covid-19

In this presentation, Arthur Kim, MD, reviews recent EUAs for baricitinib, bamlanivimab, and casirivimab/imdevimab, as well as NIH guideline recommendations for ivermectin.
Arthur Kim, MD
Released: January 25, 2021

Information on this Educational Activity

Faculty

Arthur Kim, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he served as a site PI for an NIH-funded trial of casirivimab/imdevimab.

Program Medium

This program has been made available online.

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings